Hyaluronic Acid 0.1% | Tretinoin 0.05%
Hyaluronic Acid 0.1% | Tretinoin 0.05% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
Hyaluronic Acid 0.1% | Tretinoin 0.05% is a compounded topical cream or gel combining a humectant/barrier-support agent with a retinoid, designed for prescriber-directed treatment of acne vulgaris, photoaging, and/or hyperpigmentation. Hyaluronic acid provides intense hydration to offset retinoid-induced dryness and irritation, while tretinoin acts on nuclear retinoic acid receptors to normalize keratinocyte differentiation and increase epidermal turnover. Genesis Compounding prepares this as a prescription-only, patient-specific, 503A compounded preparation not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Hyaluronic Acid 0.1% | High-molecular-weight humectant glycosaminoglycan that binds water at the skin surface, enhances hydration, reduces transepidermal water loss, and mitigates dryness and irritation associated with tretinoin use. |
| Tretinoin 0.05% | Vitamin A-derived retinoid that binds nuclear retinoic acid receptors (RARs) to normalize follicular keratinization, increase keratinocyte turnover, stimulate procollagen synthesis, and reduce comedone formation and hyperpigmentation. |
Route: Topical. Apply a thin layer to cleansed, dry affected skin (typically facial) once nightly or as directed by the prescriber. Allow skin to dry for 20–30 minutes after cleansing before application to reduce irritation. Avoid the periorbital area, nasolabial folds, and mucous membranes. Apply sunscreen daily; avoid unprotected sun exposure during tretinoin therapy.
Dosing is prescriber-determined. General guidance:
- Begin with less frequent application (every other night or 3 nights per week) to assess tolerability, then advance to nightly as tolerated.
- A pea-sized amount covers the entire face.
- Gradual introduction minimizes retinoid dermatitis (redness, peeling, flaking).
- Prescriber adjusts frequency and duration based on clinical response and tolerability.
- Tretinoin 0.05%: Binds retinoic acid receptors (RAR-α, -β, -γ), which heterodimerize with retinoid X receptors (RXRs) and bind retinoic acid response elements (RAREs) in DNA. This promotes procollagen I/III gene expression, increases keratinocyte turnover, normalizes follicular epithelial differentiation, reduces comedone formation, inhibits matrix metalloproteinases (MMPs), and decreases epidermal melanin content by accelerating pigmented keratinocyte shedding and reducing tyrosinase activity.
- Hyaluronic Acid 0.1%: Acts as a humectant by binding water (up to 1,000× its weight); interacts with CD44 and RHAMM cell surface receptors on keratinocytes and fibroblasts, supporting epidermal barrier integrity and reducing transepidermal water loss (TEWL). Counteracts the desiccating effects of tretinoin, improving tolerability and adherence.
This combination is indicated in prescriber-directed management of acne vulgaris, photodamage (fine lines, mottled pigmentation, surface roughness), and post-inflammatory hyperpigmentation. Hyaluronic acid inclusion addresses the well-recognized tolerability limitation of tretinoin monotherapy (retinoid dermatitis), allowing more patients to maintain consistent therapy.
Monitoring: Assess for retinoid dermatitis (erythema, peeling, desquamation) at follow-up. Counsel patients on sunscreen adherence. For women of childbearing potential: tretinoin is teratogenic systemically; topical exposure is minimal, but prescriber should assess pregnancy risk.
Contraindications:
- Known hypersensitivity to tretinoin, retinoids, or formulation components.
- Pregnancy: topical tretinoin is classified Pregnancy Category C (systemic absorption is low but non-zero); prescriber assessment required.
Warnings & Precautions:
- Photosensitivity: tretinoin increases UV sensitivity; rigorous daily sunscreen use is mandatory.
- Retinoid dermatitis: erythema, burning, peeling — typically self-limited; frequency reduction may be needed.
- Avoid concurrent use of other potentially irritating topicals (benzoyl peroxide, salicylic acid, glycolic acid) until tolerability is established.
- Waxing/depilation: avoid waxing treated areas due to risk of skin removal.
Drug Interactions:
- Topical products containing sulfur, resorcinol, salicylic acid, or alcohol may increase skin irritation.
- Concurrent use of photosensitizing medications increases UV burn risk.
Common Side Effects: Skin dryness, erythema, peeling, desquamation, stinging, and photosensitivity — particularly in the first 2–6 weeks. Hyaluronic acid helps mitigate dryness and peeling.
Store at room temperature (15°C–25°C / 59°F–77°F). Keep away from excessive heat and direct sunlight. Keep container tightly closed. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding. Tretinoin is light-sensitive; store in opaque or amber container.
Why is hyaluronic acid combined with tretinoin?
Tretinoin commonly causes dryness, peeling, and irritation — known as retinoid dermatitis. Hyaluronic acid is a powerful humectant that attracts and binds moisture to the skin surface, reducing these side effects and improving patient comfort and adherence to tretinoin therapy.
When should I apply this medication?
Apply nightly to clean, dry skin. Wait 20–30 minutes after washing to reduce irritation. Do not apply to wet skin. Use a broad-spectrum sunscreen every morning, as tretinoin increases sun sensitivity.
How long before I see results?
Most patients see initial improvements in skin texture in 6–12 weeks; more significant changes in pigmentation and fine lines may take 3–6 months of consistent use. Results depend on adherence, skin type, and the specific indication being treated.
Is this safe during pregnancy?
Tretinoin is teratogenic when taken systemically. While topical absorption is low, prescribers generally advise avoiding tretinoin-containing products during pregnancy. Discuss this with your prescriber if you are pregnant or planning to become pregnant.
Is this FDA-approved?
No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding, not FDA-approved as a compounded drug.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.